

Department of Veterans Affairs

§4.117

| | Rating |
|---|--------|
| Vaginal fecal leakage one to three times per week requiring wearing of pad | 30 |
| Vaginal fecal leakage less than once a week | 10 |
| Without leakage | 0 |
| 7625 Fistula, urethrovaginal: | |
| Multiple urethrovaginal fistulae | 100 |
| Requiring the use of an appliance or the wearing of absorbent materials which must be changed more than four times per day | 60 |
| Requiring the wearing of absorbent materials which must be changed two to four times per day | 40 |
| Requiring the wearing of absorbent materials which must be changed less than two times per day | 20 |
| 7626 Breast, surgery of: | |
| Following radical mastectomy: | |
| Both | 180 |
| One | 150 |
| Following modified radical mastectomy: | |
| Both | 160 |
| One | 140 |
| Following simple mastectomy or wide local excision with significant alteration of size or form: | |
| Both | 150 |
| One | 130 |
| Following wide local excision without significant alteration of size or form: | |
| Both or one | 0 |
| Note: For VA purposes: | |
| (1) <i>Radical mastectomy</i> means removal of the entire breast, underlying pectoral muscles, and regional lymph nodes up to the coracoclavicular ligament.. | |
| (2) <i>Modified radical mastectomy</i> means removal of the entire breast and axillary lymph nodes (in continuity with the breast). Pectoral muscles are left intact.. | |
| (3) <i>Simple (or total) mastectomy</i> means removal of all of the breast tissue, nipple, and a small portion of the overlying skin, but lymph nodes and muscles are left intact.. | |
| (4) <i>Wide local excision</i> (including partial mastectomy, lumpectomy, tylectomy, segmentectomy, and quadrantectomy) means removal of a portion of the breast tissue.. | |
| 7627 Malignant neoplasms of gynecological system or breast | 100 |

| | Rating |
|--|--------|
| Note: A rating of 100 percent shall continue beyond the cessation of any surgical, X-ray, antineoplastic chemotherapy or other therapeutic procedure. Six months after discontinuance of such treatment, the appropriate disability rating shall be determined by mandatory VA examination. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of §3.105(e) of this chapter. If there has been no local recurrence or metastasis, rate on residuals. | |
| 7628 Benign neoplasms of the gynecological system or breast. Rate according to impairment in function of the urinary or gynecological systems, or skin. | |
| 7629 Endometriosis: | |
| Lesions involving bowel or bladder confirmed by laparoscopy, pelvic pain or heavy or irregular bleeding not controlled by treatment, and bowel or bladder symptoms | 50 |
| Pelvic pain or heavy or irregular bleeding not controlled by treatment | 30 |
| Pelvic pain or heavy or irregular bleeding requiring continuous treatment for control | 10 |
| Note: Diagnosis of endometriosis must be substantiated by laparoscopy. | |
| ¹ Review for entitlement to special monthly compensation under §3.350 of this chapter. | |

[60 FR 19855, Apr. 21, 1995, as amended at 67 FR 6874, Feb. 14, 2002; 67 FR 37695, May 30, 2002]

THE HEMIC AND LYMPHATIC SYSTEMS

§4.117 Schedule of ratings—hemic and lymphatic systems.

| | Rating |
|--|--------|
| 7700 Anemia, hypochromic-microcytic and megaloblastic, such as iron-deficiency and pernicious anemia: | |
| Hemoglobin 5gm/100ml or less, with findings such as high output congestive heart failure or dyspnea at rest | 100 |
| Hemoglobin 7gm/100ml or less, with findings such as dyspnea on mild exertion, cardiomegaly, tachycardia (100 to 120 beats per minute) or syncope (three episodes in the last six months) | 70 |
| Hemoglobin 8gm/100ml or less, with findings such as weakness, easy fatigability, headaches, lightheadedness, or shortness of breath | 30 |
| Hemoglobin 10gm/100ml or less with findings such as weakness, easy fatigability or headaches | 10 |
| Hemoglobin 10gm/100ml or less, asymptomatic | 0 |
| NOTE: Evaluate complications of pernicious anemia, such as dementia or peripheral neuropathy, separately. | |
| 7702 Agranulocytosis, acute: | |
| Requiring bone marrow transplant, or; requiring transfusion of platelets or red cells at least once every six weeks, or; infections recurring at least once every six weeks | 100 |

§ 4.118

38 CFR Ch. I (7–1–12 Edition)

| | Rating |
|--|--------|
| Requiring transfusion of platelets or red cells at least once every three months, or; infections recurring at least once every three months | 60 |
| Requiring transfusion of platelets or red cells at least once per year but less than once every three months, or; infections recurring at least once per year but less than once every three months | 30 |
| Requiring continuous medication for control | 10 |
| NOTE: The 100 percent rating for bone marrow transplant shall be assigned as of the date of hospital admission and shall continue with a mandatory VA examination six months following hospital discharge. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of § 3.105(e) of this chapter. | |
| 7703 Leukemia: | |
| With active disease or during a treatment phase | 100 |
| Otherwise rate as anemia (code 7700) or aplastic anemia (code 7716), whichever would result in the greater benefit. | |
| NOTE: The 100 percent rating shall continue beyond the cessation of any surgical, radiation, antineoplastic chemotherapy or other therapeutic procedures. Six months after discontinuance of such treatment, the appropriate disability rating shall be determined by mandatory VA examination. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of § 3.105(e) of this chapter. If there has been no recurrence, rate on residuals. | |
| 7704 Polycythemia vera: | |
| During periods of treatment with myelosuppressants and for three months following cessation of myelosuppressant therapy | 100 |
| Requiring phlebotomy | 40 |
| Stable, with or without continuous medication | 10 |
| NOTE: Rate complications such as hypertension, gout, stroke or thrombotic disease separately. | |
| 7705 Thrombocytopenia, primary, idiopathic or immune: | |
| Platelet count of less than 20,000, with active bleeding, requiring treatment with medication and transfusions | 100 |
| Platelet count between 20,000 and 70,000, not requiring treatment, without bleeding | 70 |
| Stable platelet count between 70,000 and 100,000, without bleeding | 30 |
| Stable platelet count of 100,000 or more, without bleeding | 0 |
| 7706 Splenectomy | 20 |
| NOTE: Rate complications such as systemic infections with encapsulated bacteria separately. | |
| 7707 Spleen, injury of, healed. Rate for any residuals. | |
| 7709 Hodgkin's disease: | |
| With active disease or during a treatment phase | 100 |
| NOTE: The 100 percent rating shall continue beyond the cessation of any surgical, radiation, antineoplastic chemotherapy or other therapeutic procedures. Six months after discontinuance of such treatment, the appropriate disability rating shall be determined by mandatory VA examination. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of § 3.105(e) of this chapter. If there has been no local recurrence or metastasis, rate on residuals. | |

| | Rating |
|--|--------|
| 7710 Adenitis, tuberculous, active or inactive. Rate under §§ 4.88c or 4.89 of this part, whichever is appropriate. | |
| 7714 Sickle cell anemia: | |
| With repeated painful crises, occurring in skin, joints, bones or any major organs caused by hemolysis and sickling of red blood cells, with anemia, thrombosis and infarction, with symptoms precluding even light manual labor | 100 |
| With painful crises several times a year or with symptoms precluding other than light manual labor | 60 |
| Following repeated hemolytic sickling crises with continuing impairment of health | 30 |
| Asymptomatic, established case in remission, but with identifiable organ impairment | 10 |
| NOTE: Sickle cell trait alone, without a history of directly attributable pathological findings, is not a ratable disability. Cases of symptomatic sickle cell trait will be forwarded to the Director, Compensation and Pension Service, for consideration under § 3.321(b)(1) of this chapter. | |
| 7715 Non-Hodgkin's lymphoma: | |
| With active disease or during a treatment phase | 100 |
| NOTE: The 100 percent rating shall continue beyond the cessation of any surgical, radiation, antineoplastic chemotherapy or other therapeutic procedures. Six months after discontinuance of such treatment, the appropriate disability rating shall be determined by mandatory VA examination. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of § 3.105(e) of this chapter. If there has been no local recurrence or metastasis, rate on residuals. | |
| 7716 Aplastic anemia: | |
| Requiring bone marrow transplant, or; requiring transfusion of platelets or red cells at least once every six weeks, or; infections recurring at least once every six weeks | 100 |
| Requiring transfusion of platelets or red cells at least once every three months, or; infections recurring at least once every three months | 60 |
| Requiring transfusion of platelets or red cells at least once per year but less than once every three months, or; infections recurring at least once per year but less than once every three months | 30 |
| Requiring continuous medication for control | 10 |
| NOTE: The 100 percent rating for bone marrow transplant shall be assigned as of the date of hospital admission and shall continue with a mandatory VA examination six months following hospital discharge. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of § 3.105(e) of this chapter. | |
| 7717 AL amyloidosis (primary amyloidosis) | 100 |

[60 FR 49227, Sept. 22, 1995, as amended at 77 FR 6467, Feb. 8, 2012]

THE SKIN

§ 4.118 Schedule of ratings—skin.

A veteran whose scars were rated by VA under a prior version of diagnostic codes 7800, 7801, 7802, 7803, 7804, or 7805,